Abstract

The present invention relates to a controlled release formulation comprising: Mirabegron or a pharmaceutically acceptable salt thereof; an isomalt; and a sustained release agent. Disclosed is a formulation in which Mirabegron, a medication, does not decompose, and thus the therapeutic effect thereof can be maintained constant during long-term storage. Moreover, Mirabegron can be released stably and sustainably in vivo, and thus a sufficient medicinal effect can be exhibited even when the formulation is administered once a day.

IPC Classes  ?

• A61K 9/20 - Pills, lozenges or tablets
• A61K 9/28 - DrageesCoated pills or tablets
• A61K 31/426 - 1,3-Thiazoles

Abstract

The present invention provides an apixaban pharmaceutical formulation for delayed release of drug, comprising: a core comprising at least one selected from the group consisting of an apixaban and a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier; and a coated layer for the core, characterized in that a release lag time is from 5 to 360 minutes and 60% or more by weight of the apixaban dissolve within 60 minutes after the release lag time, wherein the release lag time is defined as the time at which the dissolution rate of apixaban is detected to be less than 10% by weight, as measured in 900 mL of dissolution medium at 37℃ using a USP Apparatus 2 at a rotation speed of 75 rpm; and a method for preparing the same.

IPC Classes  ?

• A61K 9/28 - DrageesCoated pills or tablets
• A61K 9/20 - Pills, lozenges or tablets
• A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
• A61P 9/00 - Drugs for disorders of the cardiovascular system

Abstract

The present invention relates to a breast cancer diagnosis composition using multiple autobodies and a breast cancer diagnosis kit using same. When used as a breast cancer diagnosis marker, a recombinant protein relevant to a breast cancer-related autoantibody allows breast cancer to be diagnosed using a non-invasive biological sample, such as blood, plasma, or serum, alone, even without any biopsy. The combined use of recombinant proteins capable of detecting breast cancer-related autoantibodies brings about higher accuracy in the diagnosis of breast cancer than the individual use of the recombinant proteins and can be used for breast cancer diagnosis kit having excellent specificity over other carcinomas.

IPC Classes  ?

• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
• G01N 33/564 - ImmunoassayBiospecific binding assayMaterials therefor for pre-existing immune complex or autoimmune disease
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
• C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
• C07K 14/81 - Protease inhibitors

Abstract

Paeonia Suffruticosa Andrews including antibacterial activity, bone reinforcement, antiphlogistic activity, blood nourishment, vigoration, etc. may bring about a synergistic effect on the prevention, treatment and improvement of an inflammatory disease.

IPC Classes  ?

• A61K 36/24 - Apocynaceae (Dogbane family), e.g. plumeria or periwinkle
• A61K 36/65 - Paeoniaceae (Peony family), e.g. Chinese peony
• A61K 9/20 - Pills, lozenges or tablets
• A23L 33/105 - Plant extracts, their artificial duplicates or their derivatives

Abstract

The present invention relates to a pharmaceutical composition for preventing or treating inflammatory diseases, having a phytosterol compound or a pharmaceutically acceptable salt thereof as an active ingredient. Having therapeutic activity for inflammatory diseases, the phytosterol compound is also applicable to a quasi-drug composition, a health functional food composition, and a cosmetic composition, all of which are intended to prevent or improve inflammation. Also, a method is provided for treating an inflammatory disease by administering the pharmaceutical composition to a subject in need thereof. As a natural materials, the phytosterol compound can be used as a safe therapeutic relatively free of fungal infection or other side-effects, compared to synthetic medicines.

IPC Classes  ?

• A61K 31/56 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids
• A61K 31/575 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
• A61K 31/7028 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]

Abstract

The present invention relates to a novel compound, named 2-ethoxy-4-(3-hydroxy-2-oxopropyl) phenyl 2-oxoacetate or a pharmaceutically acceptable salt thereof, which shows anti-inflammatory activity, and a method for preparing the same. Also, a pharmaceutical composition for preventing or treating inflammatory diseases, having the compound or a pharmaceutically acceptable salt thereof as an active ingredient is disclosed. Having therapeutic activity for inflammatory diseases, the phenylester compound is also applicable to a quasi-drug composition, a health functional food composition, and a cosmetic composition, all of which are intended to prevent or improve inflammation. Also, a method is provided for treating an inflammatory disease by administering the pharmaceutical composition to a subject in need thereof. As a natural materials, the novel phenylester compound can be used as a safe therapeutic relatively free of fungal infection or other side-effects, compared to synthetic medicines.

IPC Classes  ?

• C07C 69/736 - Ethers the hydroxy group of the ester being etherified with a hydroxy compound having the hydroxy group bound to a carbon atom of a six-membered aromatic ring
• A61K 31/216 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
• A61K 36/65 - Paeoniaceae (Peony family), e.g. Chinese peony
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]

Abstract

The present invention relates to a pharmaceutical composition for preventing and treating an inflammatory disease, including a mixture of extracts from Trachelospermi Caulis and Paeonia Suffruticosa Andrews as an active ingredient and method for preparing the same. Also, a quasi-drug composition, a health functional food composition and a cosmetic composition, all based on the mixture, are provided for preventing or improving inflammation. In addition, the present invention relates to a method for treating an inflammatory disease by administering the pharmaceutical composition to a subject suspected of having the inflammatory disease. Containing the extract mixture, the composition exhibits excellent anti-inflammatory activity and edema-suppressing activity, compared to individual extracts, and thus can be applied to the prevention, treatment or improvement of an inflammatory disease. As natural materials, the extracts can be used as a safe therapeutic relatively free of fungal infection or other side-effects, compared to synthetic medicines. In addition, the known physiological activities of the extracts from Trachelospermi Caulis and Paeonia Suffruticosa Andrews including antibacterial activity, bone reinforcement, antiphlogistic activity, blood nourishment, vigoration, etc. may bring about a synergistic effect on the prevention, treatment and improvement of an inflammatory disease.

IPC Classes  ?

• A61K 36/24 - Apocynaceae (Dogbane family), e.g. plumeria or periwinkle
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]

Abstract

Pyrola japonica in a predetermined range thereby exhibiting superior on therapeutic effects for the treatment of pains, acute inflammation, secretion of enzymes associated with factors inducing inflammation, and production of NO, iNOS, etc., as compared to those prepared from single herbal drugs, thus being useful in the prevention and treatment of inflammatory diseases such as arthritis.

IPC Classes  ?

• A61K 36/00 - Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines